Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EphA2-targeted CAR-DC and CAR-T in NSCLC
NCT06972576Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2025
- Primary completion
- Apr 2026
- Modality
- Whole Cell Cancer Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EphA2-targeted CAR-T Cells and EphA2-targeted CAR-DCs in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Incidence and severity of adverse events at 3 months and Remission Rate at 3 months. Started May 2025; status: recruiting.
02
Drugs
EphA2-targeted CAR-T CellsEphA2-targeted CAR-DCs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06972576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972576.